Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis A Clinical Trial

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis A Clinical Trial

Rationale: The cystic fibrosis (CF) modulator drug, elexacaftor/tezacaftor/ivacaftor (ETI), proved highly effective in controlled clinical trials for individuals with at least one F508del allele, which occurs in at least 85% of people with CF. Objectives: PROMISE is a postapproval study to understan...

Full description

Bibliographic Details
Main Authors: Clancy, J.P (Author), Donaldson, S.H (Author), Frederick, C.A (Author), Freedman, S.D (Author), Gelfond, D. (Author), Heltshe, S.L (Author), Hoffman, L.R (Author), Kelly, A. (Author), Kirby, S. (Author), Kloster, M.H (Author), Narkewicz, M.R (Author), Nichols, D.P (Author), Paynter, A.C (Author), Pittman, J.E (Author), Ratjen, F. (Author), Rosenfeld, M. (Author), Rowe, S.M (Author), Sagel, S.D (Author), Schwarzenberg, S.J (Author), Singh, P.K (Author), Solomon, G.M (Author), Stalvey, M.S (Author), the PROMISE Study Group (Author), Van Dalfsen, J.M (Author)
Format: Article
Language:English
Published: American Thoracic Society 2022
Subjects:
adult
allele
antibiotic agent
antibiotic therapy
Article
body mass
chloride
clinical effectiveness
clinical outcome
Clinical trial
controlled study
corticosteroid
cystic fibrosis
Cystic fibrosis
elexacaftor plus ivacaftor plus tezacaftor
Elexacaftor/tezacaftor/ivacaftor
female
forced expiratory volume
forced vital capacity
genotype
human
ivacaftor
ivacaftor plus lumacaftor
ivacaftor plus tezacaftor
lung function
major clinical study
male
Modulators
observational study
patient-reported outcome
prevalence
PROMISE
prospective study
spirometry
treatment outcome
United States
World Health Organization
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items